Remdesivir in Very Old Patients (≥80 Years) Hospitalized with COVID-19 : Real World Data from the SEMI-COVID-19 Registry
(1) Background: Large cohort studies of patients with COVID-19 treated with remdesivir have reported improved clinical outcomes, but data on older patients are scarce. Objective: This work aims to assess the potential benefit of remdesivir in unvaccinated very old patients hospitalized with COVID-19; (2) Methods: This is a retrospective analysis of patients ≥ 80 years hospitalized in Spain between 15 July and 31 December 2020 (SEMI-COVID-19 Registry). Differences in 30-day all-cause mortality were adjusted using a multivariable regression analysis. (3) Results: Of the 4331 patients admitted, 1312 (30.3%) were ≥80 years. Very old patients treated with remdesivir (n: 140, 10.7%) had a lower mortality rate than those not treated with remdesivir (OR (95% CI): 0.45 (0.29−0.69)). After multivariable adjustment by age, sex, and variables associated with lower mortality (place of COVID-19 acquisition; degree of dependence; comorbidities; dementia; duration of symptoms; admission qSOFA; chest X-ray; D-dimer; and treatment with corticosteroids, tocilizumab, beta-lactams, macrolides, and high-flow nasal canula oxygen), the use of remdesivir remained associated with a lower 30-day all-cause mortality rate (adjusted OR (95% CI): 0.40 (0.22−0.61) (p < 0.001)). (4) Conclusions: Remdesivir may reduce mortality in very old patients hospitalized with COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Journal of clinical medicine - 11(2022), 13 vom: 29. Juni |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ramos-Rincon, Jose-Manuel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Age ≥ 80 |
|---|
| Anmerkungen: |
Date Revised 08.03.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jcm11133769 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343275481 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343275481 | ||
| 003 | DE-627 | ||
| 005 | 20231226020047.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm11133769 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1144.xml |
| 035 | |a (DE-627)NLM343275481 | ||
| 035 | |a (NLM)35807058 | ||
| 035 | |a (PII)3769 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ramos-Rincon, Jose-Manuel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Remdesivir in Very Old Patients (≥80 Years) Hospitalized with COVID-19 |b Real World Data from the SEMI-COVID-19 Registry |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.03.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a (1) Background: Large cohort studies of patients with COVID-19 treated with remdesivir have reported improved clinical outcomes, but data on older patients are scarce. Objective: This work aims to assess the potential benefit of remdesivir in unvaccinated very old patients hospitalized with COVID-19; (2) Methods: This is a retrospective analysis of patients ≥ 80 years hospitalized in Spain between 15 July and 31 December 2020 (SEMI-COVID-19 Registry). Differences in 30-day all-cause mortality were adjusted using a multivariable regression analysis. (3) Results: Of the 4331 patients admitted, 1312 (30.3%) were ≥80 years. Very old patients treated with remdesivir (n: 140, 10.7%) had a lower mortality rate than those not treated with remdesivir (OR (95% CI): 0.45 (0.29−0.69)). After multivariable adjustment by age, sex, and variables associated with lower mortality (place of COVID-19 acquisition; degree of dependence; comorbidities; dementia; duration of symptoms; admission qSOFA; chest X-ray; D-dimer; and treatment with corticosteroids, tocilizumab, beta-lactams, macrolides, and high-flow nasal canula oxygen), the use of remdesivir remained associated with a lower 30-day all-cause mortality rate (adjusted OR (95% CI): 0.40 (0.22−0.61) (p < 0.001)). (4) Conclusions: Remdesivir may reduce mortality in very old patients hospitalized with COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Spain | |
| 650 | 4 | |a age ≥ 80 | |
| 650 | 4 | |a mortality | |
| 650 | 4 | |a remdesivir | |
| 700 | 1 | |a López-Carmona, María-Dolores |e verfasserin |4 aut | |
| 700 | 1 | |a Cobos-Palacios, Lidia |e verfasserin |4 aut | |
| 700 | 1 | |a López-Sampalo, Almudena |e verfasserin |4 aut | |
| 700 | 1 | |a Rubio-Rivas, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Martín-Escalante, María-Dolores |e verfasserin |4 aut | |
| 700 | 1 | |a de-Cossio-Tejido, Santiago |e verfasserin |4 aut | |
| 700 | 1 | |a Taboada-Martínez, María-Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Muiño-Miguez, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Areses-Manrique, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez-Cilleros, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Tuñón-de-Almeida, Carlota |e verfasserin |4 aut | |
| 700 | 1 | |a Abella-Vázquez, Lucy |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Gonzalez, Angel-Luís |e verfasserin |4 aut | |
| 700 | 1 | |a Díez-García, Luis-Felipe |e verfasserin |4 aut | |
| 700 | 1 | |a Ripper, Carlos-Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Asensi, Victor |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez-Pascual, Angeles |e verfasserin |4 aut | |
| 700 | 1 | |a Guisado-Vasco, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Lumbreras-Bermejo, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez-Huelgas, Ricardo |e verfasserin |4 aut | |
| 700 | 1 | |a On Behalf Of The Semi-Covid-Network |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical medicine |d 2012 |g 11(2022), 13 vom: 29. Juni |w (DE-627)NLM230666310 |x 2077-0383 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2022 |g number:13 |g day:29 |g month:06 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jcm11133769 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2022 |e 13 |b 29 |c 06 | ||